Indications:
● Treatment and management of schizophrenia.
● Acute treatment of manic or mixed episodes associated with bipolar I disorder.
Administration Guidelines:
● Sublingual Administration: Saphris tablets are to be placed under the tongue and allowed to dissolve completely, enhancing the drug's bioavailability.
● Patients are advised not to eat or drink for 10 minutes after taking Saphris to ensure optimal absorption.
Dosage Forms:
● Saphris is available in sublingual tablets, typically in 5 mg and 10 mg dosages.
Safety Preclusions
Pregnancy and Breastfeeding:
● Caution is advised when prescribing Saphris to pregnant or breastfeeding mothers, considering the potential risks and benefits, as its safety in these populations is not definitively established.
Long-term Use:
● Regular monitoring by healthcare providers is essential during long-term use of Saphris, focusing on managing any side effects and assessing the ongoing effectiveness of the medication.
Drug Interactions:
● Saphris can interact with several medications, including CNS depressants and drugs known to affect the serotoninergic neurotransmitter systems. Patients should provide a full medication history to avoid adverse interactions.
|
Reviews
There are no reviews yet.